← Back to Search

Monoclonal Antibodies

Rituximab + Immunotherapy for Follicular Lymphoma

Phase 1
Waitlist Available
Led By Caron A. Jacobson, MD
Research Sponsored by Dana-Farber Cancer Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Study Summary

This trial is testing if these drugs can help treat people with follicular lymphoma.

Who is the study for?
This trial is for adults over 18 with follicular lymphoma that's relapsed after treatment or hasn't been treated yet, except those with severe allergies to monoclonal antibodies, autoimmune diseases, active infections, other cancers within the last three years (some exceptions apply), and certain heart conditions. Participants need functioning major organs and can't be pregnant or breastfeeding.Check my eligibility
What is being tested?
The study tests combinations of Rituximab with new drugs Utomilumab and Avelumab as potential treatments for follicular lymphoma. It aims to find out how well these drug combos work together in patients who have had previous treatments or are newly diagnosed.See study design
What are the potential side effects?
Possible side effects include allergic reactions to the drugs, immune system complications potentially affecting various organs, fatigue, infusion-related reactions like fever or chills, and increased risk of infections due to a weakened immune response.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Recommended phase 2 dosing
Secondary outcome measures
Complete response rate
Objective response rate
Overall Survival Rate
+8 more

Trial Design

3Treatment groups
Experimental Treatment
Group I: Rituximab+Utomilumab+PF04518600Experimental Treatment3 Interventions
Rituximab is administered intravenously per institutional standards for four weekly treatments for cycle 1 only Utomilumab is administered intravenously over 1 hour once every 4 weeks PF-04518600 is administered intravenously over 1 hour on day 1 and day 15
Group II: Rituximab+Avelumab+PF04518600Experimental Treatment3 Interventions
Rituximab is administered intravenously per institutional standards for four weekly treatments for cycle 1 only Avelumab is administered intravenously over 1 hour once every 2 weeks PF-04518600 is administered intravenously over 1 hour on day 1 and day 15
Group III: Rituximab +Utomilumab+AvelumabExperimental Treatment3 Interventions
Rituximab is administered intravenously per institutional standards for four weekly treatments for cycle 1 only Utomilumab is administered intravenously over 1 hour once every 4 weeks Avelumab is administered intravenously over 1 hour once every 2 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Avelumab
2018
Completed Phase 2
~2450
Rituximab
1999
Completed Phase 4
~1880
Utomilumab
2018
Completed Phase 2
~30

Find a Location

Who is running the clinical trial?

Dana-Farber Cancer InstituteLead Sponsor
1,079 Previous Clinical Trials
340,924 Total Patients Enrolled
PfizerIndustry Sponsor
4,567 Previous Clinical Trials
10,911,850 Total Patients Enrolled
Caron A. Jacobson, MDPrincipal InvestigatorDana-Farber Cancer Institute

Media Library

Avelumab (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT03636503 — Phase 1
Follicular Lymphoma Research Study Groups: Rituximab+Avelumab+PF04518600, Rituximab+Utomilumab+PF04518600, Rituximab +Utomilumab+Avelumab
Follicular Lymphoma Clinical Trial 2023: Avelumab Highlights & Side Effects. Trial Name: NCT03636503 — Phase 1
Avelumab (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03636503 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many healthcare facilities are conducting this research project?

"Patients can take part in this trial at Yale New-Haven Hospital (New Haven, Connecticut), Emory University (Atlanta, Georgia) and Dana Farber Cancer Institute (Boston, Massachusetts). There are also 6 additional participating medical sites."

Answered by AI

What illnesses can be alleviated by the use of Rituximab?

"Rituximab is often used to treat the mentioned therapeutic procedure, and has also been noted as a useful treatment for merkel cell carcinoma, diffuse large b-cell lymphoma (dlbcl), and pharmacotherapy."

Answered by AI

Does Rituximab pose any substantial health hazards for those taking it?

"As this is an initial clinical trial, the safety of Rituximab was estimated to be a 1 due to limited evidence regarding its efficacy."

Answered by AI

Are there vacancies yet available to participants in this medical experiment?

"At present, this medical trial is not recruiting patients. Although initially posted on October 30th 2018 and last edited on March 17th 2022, the study has since closed its application window. However, there are an abundance of trials that still require participants - 2236 studies to be exact."

Answered by AI

Are there any comparable studies that have made use of Rituximab?

"As of now, there are 517 clinical trials researching Rituximab with 102 in their final stages. These studies take place mainly around Houston, Texas but have locations spread across 17973 other spots."

Answered by AI

What is the aggregate amount of people participating in this experiment?

"This trial is not presently accepting new participants. It was initially made public on October 30th 2018 and updated lastly on March 17th 2022. However, there are currently 1,719 trials for lymphoma, follicular recruiting patients as well as 517 concerning Rituximab still searching for individuals to join their research teams."

Answered by AI
~4 spots leftby Apr 2025